These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 36829087)

  • 1. A retrospective survey of patients with hereditary transthyretin-mediated (hATTR) amyloidosis treated with patisiran in real-world clinical practice in Belgium.
    De Bleecker JL; Claeys KG; Delstanche S; Van Parys V; Baets J; Tilleux S; Remiche G
    Acta Neurol Belg; 2023 Jun; 123(3):1029-1037. PubMed ID: 36829087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure-Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis.
    Zhang X; Goel V; Attarwala H; Sweetser MT; Clausen VA; Robbie GJ
    J Clin Pharmacol; 2020 Jan; 60(1):37-49. PubMed ID: 31322739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis: The APOLLO Study.
    Minamisawa M; Claggett B; Adams D; Kristen AV; Merlini G; Slama MS; Dispenzieri A; Shah AM; Falk RH; Karsten V; Sweetser MT; Chen J; Riese R; Vest J; Solomon SD
    JAMA Cardiol; 2019 May; 4(5):466-472. PubMed ID: 30878017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.
    Obici L; Berk JL; González-Duarte A; Coelho T; Gillmore J; Schmidt HH; Schilling M; Yamashita T; Labeyrie C; Brannagan TH; Ajroud-Driss S; Gorevic P; Kristen AV; Franklin J; Chen J; Sweetser MT; Wang JJ; Adams D
    Amyloid; 2020 Sep; 27(3):153-162. PubMed ID: 32131641
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis.
    Solomon SD; Adams D; Kristen A; Grogan M; González-Duarte A; Maurer MS; Merlini G; Damy T; Slama MS; Brannagan TH; Dispenzieri A; Berk JL; Shah AM; Garg P; Vaishnaw A; Karsten V; Chen J; Gollob J; Vest J; Suhr O
    Circulation; 2019 Jan; 139(4):431-443. PubMed ID: 30586695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study.
    Adams D; Polydefkis M; González-Duarte A; Wixner J; Kristen AV; Schmidt HH; Berk JL; Losada López IA; Dispenzieri A; Quan D; Conceição IM; Slama MS; Gillmore JD; Kyriakides T; Ajroud-Driss S; Waddington-Cruz M; Mezei MM; Planté-Bordeneuve V; Attarian S; Mauricio E; Brannagan TH; Ueda M; Aldinc E; Wang JJ; White MT; Vest J; Berber E; Sweetser MT; Coelho T;
    Lancet Neurol; 2021 Jan; 20(1):49-59. PubMed ID: 33212063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.
    González-Duarte A; Berk JL; Quan D; Mauermann ML; Schmidt HH; Polydefkis M; Waddington-Cruz M; Ueda M; Conceição IM; Kristen AV; Coelho T; Cauquil CA; Tard C; Merkel M; Aldinc E; Chen J; Sweetser MT; Wang JJ; Adams D
    J Neurol; 2020 Mar; 267(3):703-712. PubMed ID: 31728713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patisiran, an RNAi therapeutic for hereditary transthyretin-mediated amyloidosis: Sub-analysis in Taiwanese patients from the APOLLO study.
    Lin KP; Yang CC; Lee YC; Lee MJ; Vest J; Sweetser MT; White MT; Badri P; Hsieh ST; Chao CC
    J Formos Med Assoc; 2024 Sep; 123(9):975-984. PubMed ID: 38548524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis.
    Coelho T; Adams D; Conceição I; Waddington-Cruz M; Schmidt HH; Buades J; Campistol J; Berk JL; Polydefkis M; Wang JJ; Chen J; Sweetser MT; Gollob J; Suhr OB
    Orphanet J Rare Dis; 2020 Jul; 15(1):179. PubMed ID: 32641071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Canadian Guidelines for Hereditary Transthyretin Amyloidosis Polyneuropathy Management.
    Alcantara M; Mezei MM; Baker SK; Breiner A; Dhawan P; Fiander A; Fine NM; Hahn C; Katzberg HD; Khayambashi S; Massie R; Matte G; Putko B; Siddiqi Z; Delgado D; Bril V
    Can J Neurol Sci; 2022 Jan; 49(1):7-18. PubMed ID: 33631091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study.
    Ticau S; Aldinc E; Polydefkis M; Adams D; Coelho T; Ueda M; Hale C; Vest J; Nioi P;
    Amyloid; 2024 Mar; 31(1):1-11. PubMed ID: 37469249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and Pharmacodynamics of Patisiran in Patients with hATTR Amyloidosis and with Polyneuropathy After Liver Transplantation.
    Badri P; Habtemariam B; Melch M; Clausen VA; Arum S; Li X; Jay PY; Vest J; Robbie GJ
    Clin Pharmacokinet; 2023 Oct; 62(10):1509-1522. PubMed ID: 37639169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel RNA-targeted therapies for hereditary ATTR amyloidosis and their impact on the autonomic nervous system.
    Conceição I
    Clin Auton Res; 2019 Sep; 29(Suppl 1):11-17. PubMed ID: 31399774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [de novo hATTR amyloidosis after domino transplantation of a donor's liver: a case report for the use of Patisiran].
    Schmidt M; Yilmaz A; Bietenbeck M; Schilling M; Röcken C; Schmidt HH
    Z Gastroenterol; 2022 Nov; 60(11):1659-1664. PubMed ID: 35533685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indirect treatment comparison of the efficacy of patisiran and inotersen for hereditary transthyretin-mediated amyloidosis with polyneuropathy.
    Gorevic P; Franklin J; Chen J; Sajeev G; Wang JCH; Lin H
    Expert Opin Pharmacother; 2021 Jan; 22(1):121-129. PubMed ID: 32892660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation.
    Schmidt HH; Wixner J; Planté-Bordeneuve V; Muñoz-Beamud F; Lladó L; Gillmore JD; Mazzeo A; Li X; Arum S; Jay PY; Adams D;
    Am J Transplant; 2022 Jun; 22(6):1646-1657. PubMed ID: 35213769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy.
    Planté-Bordeneuve V; Lin H; Gollob J; Agarwal S; Betts M; Fahrbach K; Chitnis M; Polydefkis M
    Expert Opin Pharmacother; 2019 Mar; 20(4):473-481. PubMed ID: 30489166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vutrisiran: A Review in Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis.
    Nie T; Heo YA; Shirley M
    Drugs; 2023 Oct; 83(15):1425-1432. PubMed ID: 37728865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy.
    Adams D; Suhr OB; Dyck PJ; Litchy WJ; Leahy RG; Chen J; Gollob J; Coelho T
    BMC Neurol; 2017 Sep; 17(1):181. PubMed ID: 28893208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leading RNA Interference Therapeutics Part 1: Silencing Hereditary Transthyretin Amyloidosis, with a Focus on Patisiran.
    Titze-de-Almeida SS; Brandão PRP; Faber I; Titze-de-Almeida R
    Mol Diagn Ther; 2020 Feb; 24(1):49-59. PubMed ID: 31701435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.